Philips’ investors can ill-afford another jolt to their nerves - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
飞利浦

Philips’ investors can ill-afford another jolt to their nerves

Investors in the Dutch healthcare conglomerate had until this week been enjoying a restorative patch

Some companies, it seems, receive the benefit of the doubt even if their performance is a little ho-hum. They can, for example, highlight weak Chinese demand and get away with a mere share price ripple. Other stocks take a razor-sharp cut on every lump and bump. 

Philips is a case in point. Investors in the Dutch healthcare conglomerate, which makes everything from diagnostic machines to electric shavers, had until this week been enjoying a restorative patch. Legal woes over malfunctioning sleep apnoea machines had been resolved faster and more cheaply than feared, and sales seemed to be heading in the right direction.

But a stumble has undone much of the progress. Philips’ stock has fallen 15 per cent since it released soft third-quarter results on Monday. While Italy’s Agnelli family — who made a big investment in the stock in August 2023 through their public vehicle Exor — is still in the money, this week marks a blow for those who had more recently got behind Philips’ turnaround story.

Investors must be wondering what exactly hit them. The issues Philips highlighted at third-quarter results are hardly unheard of. An anti-corruption drive at Chinese hospitals is slowing procurement of diagnostics machines — a headwind that drove guidance downgrades at rivals Siemens Healthineers and GE Healthcare after second-quarter results, points out Lisa Clive at Bernstein. And while a double-digit fall in personal care sales in China is surprising in its magnitude, the weakness of Chinese consumer demand has been widely flagged across industries.

Meanwhile, results outside China are strong. Operating margins remain healthy despite slower than expected sales. Philips does not look expensive, either. It trades on 15 times next year’s — reduced — earnings expectations despite double-digit EPS growth through to 2026, on Barclays estimates. Siemens Healthineers trades on more than 19 times.

The best explanation for the share price reaction is that Philips is suffering from sticky negative sentiment, a malady that can afflict companies that have severely spooked the market in recent history.

Curing it requires not just solving one problem, no matter how major. It requires solving all of them. That’s something that GSK, reporting on Wednesday, will be acutely aware of. Following the resolution of the Zantac heartburn medicine legal overhang, analysts are now fretting over the strength of its vaccine sales.

Traumatised investors require a long period of peace and quiet to recover their composure. Philips cannot afford another jolt to their nerves.

camilla.palladino@ft.com

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

美国通胀会再次抬头吗?

欧元区通胀将以多快的速度上升?欧洲天然气价格会继续上涨吗?

俄罗斯招募也门雇佣军在乌克兰作战

与胡塞武装有关的神秘公司诱骗男子加入莫斯科的战争机器。

令人大开眼界的时间测量新科学

在科罗拉多州没有窗户的实验室里,摆放着20台原子钟,全世界都在用它们来计时。它们几乎跟不上。

特朗普政府财政部长之争的内幕

贝森特在当选总统的宫廷内部经过激烈的影响力争夺战后获胜。

比特币和香蕉成为新的炫耀性消费品

两者都加入了无用物品的精英世界,价格越高越受欢迎。

Bluesky趁X用户流失迅速崛起,Threads未能抓住机会

在X遭遇大量用户流失之际,Meta旗下的Threads却将机会让给了只有20个员工的Bluesky。
设置字号×
最小
较小
默认
较大
最大
分享×